VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, HL McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy